SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Idorsia plans pediatric insomnia Phase 3 study for H2 2027

Idorsia plans a Phase 3 study of daridorexant for pediatric insomnia in the second half of 2027.

SquawkNews Desk

Related stories

NDR Auto Components Q2 Consolidated Revenue INR 2,440.2 Million M impact | EQUITY | Nov 04, 2026, 07:58 AM UTC NDR Auto Components Reports Q2 Consolidated Net Profit of INR 197.8 Million M impact | EQUITY | Nov 04, 2026, 07:57 AM UTC Arman Financial Services Reports Q2 Consolidated Revenue of INR 2,346.419 Million M impact | EQUITY | Nov 04, 2026, 07:56 AM UTC Arman Financial Services Reports Q2 Consolidated Net Profit of INR 514.795 Million M impact | EQUITY | Nov 04, 2026, 07:56 AM UTC Exide Industries Reports Q2 Consolidated Revenue of INR 52,918.7 Million M impact | EQUITY | Nov 04, 2026, 07:54 AM UTC UPDATE 1-UK Stocks-Factors to watch on November 4 UPDATE 1-UK Stocks-Factors to watch on November 4 Adds news, updates futures Nov 4 (Reuters) - Brita L impact | EQUITY | Nov 04, 2026, 07:53 AM UTC